DK1923064T3 - Anvendelse af aminpolymer til sænkning af serumglucose - Google Patents
Anvendelse af aminpolymer til sænkning af serumglucose Download PDFInfo
- Publication number
- DK1923064T3 DK1923064T3 DK08002418.5T DK08002418T DK1923064T3 DK 1923064 T3 DK1923064 T3 DK 1923064T3 DK 08002418 T DK08002418 T DK 08002418T DK 1923064 T3 DK1923064 T3 DK 1923064T3
- Authority
- DK
- Denmark
- Prior art keywords
- polymer
- solid
- water
- stirred
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Claims (14)
1. Anvendelse af mindst én aminpolymer til fremstilling af et medikament til det formål at reducere serumglucose hos et individ, der har behov for det, hvor medikamentet, der omfatter aminpolymeren, administreres til en voksen i et interval på mellem 3 gram og 6 gram dagligt, hvad angår aminpolymeren.
2. Anvendelse ifølge krav 1, hvor aminpolymeren er alifatisk.
3. Anvendelse ifølge krav 1 eller 2, hvor polymeren har en substituent valgt fra gruppen, der består af aminer, cyano, olefiner, phosphiner, arsiner, sulfider, dithiocarbamater, nitrater, carboxylater, phenolater, acetylacetonater og hydroxygrupper.
4. Anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor polymeren er kendetegnet ved en gentagelsesenhed med en formel valgt fra gruppen, der består af:
og salte og copolymerer deraf, hvor n er et positivt helt tal, og y og z er hele tal på en eller mere, og R, Ri, R2 og R3 uafhængigt er H eller en substitueret eller usubstitueret alkylgruppe, og X“ er en udskiftelig negativt ladet modion.
5. Anvendelse ifølge krav 4, hvor polymeren er tværbundet ved hjælp af et multifunktionelt tværbindingsmiddel.
6. Anvendelse ifølge krav 5, hvor det multifunktionelle tværbindingsmiddel er til stede i en mængde på ca. 0,5-25 vægt-%, fortrinsvis ca. 2,5-20 vægt-% baseret på den samlede vægt af monomer og tværbindingsmiddel.
7. Anvendelse ifølge krav 5, hvor tværbindingsmidlet omfatter epichlorhydrin.
8. Anvendelse ifølge krav 5, hvor polymeren er en homopolymer.
9. Anvendelse ifølge krav 5, hvor polymeren er valgt fra gruppen, der består af polyallylaminer, polydiallylaminer eller polyethylenaminer.
10. Anvendelse ifølge krav 7, hvor polymeren er en polyvinylamin.
11. Anvendelse ifølge krav 4, hvor mindst én af R, Ri, R2 og R3 i hver formel er hydrogen.
12. Anvendelse ifølge krav 5, hvor medikamentet er en del af et eller flere måltider.
13. Anvendelse ifølge krav 1, hvor polymeren er colesevelam.
14. Anvendelse ifølge krav 1, hvor polymeren er sevelamerhydrochlorid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28444501P | 2001-04-18 | 2001-04-18 | |
| US30556401P | 2001-07-13 | 2001-07-13 | |
| EP02726733A EP1392331B1 (en) | 2001-04-18 | 2002-04-10 | Use of colesevelam or sevelamer hydrogen chloride for lowering serum glucose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1923064T3 true DK1923064T3 (da) | 2017-10-02 |
Family
ID=26962623
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02726733T DK1392331T3 (da) | 2001-04-18 | 2002-04-10 | Anvendelse af colesevelam eller sevelamer, hydrogenchlorid til sænkning af serumglucoseniveauet |
| DK08002418.5T DK1923064T3 (da) | 2001-04-18 | 2002-04-10 | Anvendelse af aminpolymer til sænkning af serumglucose |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02726733T DK1392331T3 (da) | 2001-04-18 | 2002-04-10 | Anvendelse af colesevelam eller sevelamer, hydrogenchlorid til sænkning af serumglucoseniveauet |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7229613B2 (da) |
| EP (1) | EP1392331B1 (da) |
| JP (2) | JP4499363B2 (da) |
| KR (1) | KR20040018358A (da) |
| CN (1) | CN1511039A (da) |
| AT (1) | ATE390927T1 (da) |
| AU (1) | AU2002257145B2 (da) |
| BR (1) | BRPI0209134B8 (da) |
| CA (1) | CA2444046C (da) |
| CY (1) | CY1119486T1 (da) |
| DE (1) | DE60225908T2 (da) |
| DK (2) | DK1392331T3 (da) |
| ES (2) | ES2304437T3 (da) |
| MX (1) | MXPA03009568A (da) |
| NZ (1) | NZ528831A (da) |
| PT (1) | PT1923064T (da) |
| WO (1) | WO2002085377A1 (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| CN1511039A (zh) * | 2001-04-18 | 2004-07-07 | ԭ���ø� | 降低血浆葡萄糖的方法 |
| WO2004037274A1 (en) * | 2002-10-22 | 2004-05-06 | Genzyme Corporation | Amine polymers for promoting bone formation |
| US7449605B2 (en) * | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7608674B2 (en) | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7767768B2 (en) * | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| JPWO2005092349A1 (ja) * | 2004-03-26 | 2008-02-07 | 田辺三菱製薬株式会社 | インスリン抵抗性改善剤 |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| EP1830832A1 (en) * | 2004-12-30 | 2007-09-12 | Genzyme Corporation | Zinc-containing treatments for hyperphosphatemia |
| CA2620406A1 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
| CA2622693C (en) | 2005-09-15 | 2015-05-05 | Genzyme Corporation | Sachet formulation for amine polymers |
| EP1945196A2 (en) * | 2005-11-08 | 2008-07-23 | Genzyme Corporation | Magnesium-containing polymers for hyperphosphatemia |
| EP2043627A2 (en) * | 2006-07-05 | 2009-04-08 | Genzyme Corporation | Iron(ii)-containing treatments for hyperphosphatemia |
| JP2010502590A (ja) * | 2006-09-01 | 2010-01-28 | ユーエスヴィー リミテッド | セベラマー塩酸塩およびその処方物の調製のためのプロセス |
| US7964182B2 (en) * | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
| EP2066293A2 (en) | 2006-09-29 | 2009-06-10 | Genzyme Corporation | Amide dendrimer compositions |
| EP2120972A1 (en) | 2006-12-14 | 2009-11-25 | Genzyme Corporation | Amido-amine polymer compositions |
| EP2361171A4 (en) * | 2008-09-15 | 2014-11-05 | Shasun Chemicals And Drugs Ltd | PROCESS FOR PREPARING NETWORKED POLYMERS IN A NON-AQUEOUS SOLUTION |
| WO2010086881A2 (en) * | 2009-01-22 | 2010-08-05 | Usv Limited | Pharmaceutical compositions comprising phosphate-binding polymer |
| WO2014122586A1 (en) | 2013-02-08 | 2014-08-14 | Wockhardt Limited | Oral pharmaceutical composition of aliphatic amine polymer or salts thereof |
| KR20150130492A (ko) * | 2013-03-15 | 2015-11-23 | 젠자임 코포레이션 | 개선된 최종 당화 산물(ａｇｅ) 전구체의 격리제 |
| KR102512890B1 (ko) | 2014-06-13 | 2023-03-21 | 유나이티드 세러퓨틱스 코오포레이션 | 트레프로스티닐 제제 |
| MA41202A (fr) * | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| WO2018124264A1 (ja) | 2016-12-28 | 2018-07-05 | 富士フイルム株式会社 | 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法 |
| TW201922267A (zh) | 2017-10-16 | 2019-06-16 | 日商富士軟片股份有限公司 | 高磷血症治療劑 |
| WO2023023938A1 (en) * | 2021-08-24 | 2023-03-02 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Polymers, compositions and methods for treating hyperuricemia |
| EP4164659B1 (en) * | 2021-08-24 | 2024-03-27 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Polymers, compositions and methods for treating hyperuricemia |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4528847A (en) * | 1983-10-04 | 1985-07-16 | D. Halmi And Associates, Inc. | Flow metering device with recessed pressure taps |
| JPS6090243A (ja) * | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
| CA1220896A (en) * | 1983-11-10 | 1987-04-21 | Susumu Harada | Process for producing polymers of monoallylamine |
| US5468727A (en) * | 1990-12-13 | 1995-11-21 | Board Of Regents, The University Of Texas System | Methods of normalizing metabolic parameters in diabetics |
| JP3507523B2 (ja) | 1993-05-12 | 2004-03-15 | 積水化学工業株式会社 | 糖質吸収抑制剤 |
| US5487888A (en) * | 1993-05-20 | 1996-01-30 | Geltex, Inc. | Iron-binding polymers for oral administration |
| US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
| US5624963A (en) * | 1993-06-02 | 1997-04-29 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5618530A (en) * | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
| US5900475A (en) * | 1994-06-10 | 1999-05-04 | Geltex Pharmaceuticals, Inc. | Hydrophobic sequestrant for cholesterol depletion |
| US5703188A (en) * | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5667775A (en) * | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| TW474813B (en) * | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
| JP4156684B2 (ja) * | 1996-03-05 | 2008-09-24 | 三菱化学株式会社 | 高リン血症予防および／または治療剤 |
| US6203785B1 (en) * | 1996-12-30 | 2001-03-20 | Geltex Pharmaceuticals, Inc. | Poly(diallylamine)-based bile acid sequestrants |
| US5925379A (en) * | 1997-03-27 | 1999-07-20 | Geltex Pharmaceuticals, Inc. | Interpenetrating polymer networks for sequestration of bile acids |
| TW592727B (en) | 1997-04-04 | 2004-06-21 | Chugai Pharmaceutical Co Ltd | Phosphate-binding polymer preparations |
| US6423754B1 (en) | 1997-06-18 | 2002-07-23 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with polyallylamine polymers |
| FR2766195A1 (fr) * | 1997-07-21 | 1999-01-22 | Transgene Sa | Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique |
| US6083497A (en) * | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
| US6726905B1 (en) | 1997-11-05 | 2004-04-27 | Genzyme Corporation | Poly (diallylamines)-based phosphate binders |
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| AU2682499A (en) | 1998-02-17 | 1999-08-30 | Dimitri R. Kioussis | Anion binding polymers and the use thereof |
| ATE242008T1 (de) * | 1998-12-23 | 2003-06-15 | Searle Llc | Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen |
| AU7856200A (en) * | 1999-10-07 | 2001-05-10 | University Of Maryland | Sugar binding polymers and the use thereof |
| TWI241195B (en) * | 2000-04-10 | 2005-10-11 | Shionogi & Co | Preventive agent for bile acidic diarrhea |
| CN1511039A (zh) * | 2001-04-18 | 2004-07-07 | ԭ���ø� | 降低血浆葡萄糖的方法 |
| US20020198202A1 (en) * | 2001-06-07 | 2002-12-26 | Wyeth | Combination of a PTPase inhibitor and an antilipemic agent |
-
2002
- 2002-04-10 CN CNA028099958A patent/CN1511039A/zh active Pending
- 2002-04-10 PT PT80024185T patent/PT1923064T/pt unknown
- 2002-04-10 NZ NZ528831A patent/NZ528831A/en unknown
- 2002-04-10 KR KR10-2003-7013678A patent/KR20040018358A/ko not_active Application Discontinuation
- 2002-04-10 ES ES02726733T patent/ES2304437T3/es not_active Expired - Lifetime
- 2002-04-10 EP EP02726733A patent/EP1392331B1/en not_active Expired - Lifetime
- 2002-04-10 ES ES08002418.5T patent/ES2637020T3/es not_active Expired - Lifetime
- 2002-04-10 DK DK02726733T patent/DK1392331T3/da active
- 2002-04-10 CA CA2444046A patent/CA2444046C/en not_active Expired - Fee Related
- 2002-04-10 AT AT02726733T patent/ATE390927T1/de active
- 2002-04-10 DK DK08002418.5T patent/DK1923064T3/da active
- 2002-04-10 DE DE60225908T patent/DE60225908T2/de not_active Expired - Lifetime
- 2002-04-10 JP JP2002582950A patent/JP4499363B2/ja not_active Expired - Lifetime
- 2002-04-10 AU AU2002257145A patent/AU2002257145B2/en not_active Expired
- 2002-04-10 MX MXPA03009568A patent/MXPA03009568A/es unknown
- 2002-04-10 BR BR0209134-8 patent/BRPI0209134B8/pt not_active IP Right Cessation
- 2002-04-10 WO PCT/US2002/011493 patent/WO2002085377A1/en active IP Right Grant
- 2002-04-17 US US10/125,700 patent/US7229613B2/en not_active Expired - Lifetime
-
2007
- 2007-04-25 US US11/789,698 patent/US20070286841A1/en not_active Abandoned
-
2010
- 2010-01-19 JP JP2010009197A patent/JP2010090172A/ja active Pending
-
2017
- 2017-09-27 CY CY20171101019T patent/CY1119486T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2444046A1 (en) | 2002-10-31 |
| US7229613B2 (en) | 2007-06-12 |
| BRPI0209134B8 (pt) | 2021-05-25 |
| JP2004535384A (ja) | 2004-11-25 |
| CY1119486T1 (el) | 2018-03-07 |
| DE60225908T2 (de) | 2009-05-14 |
| WO2002085377A1 (en) | 2002-10-31 |
| DK1392331T3 (da) | 2008-06-23 |
| DE60225908D1 (de) | 2008-05-15 |
| JP2010090172A (ja) | 2010-04-22 |
| JP4499363B2 (ja) | 2010-07-07 |
| EP1392331A1 (en) | 2004-03-03 |
| MXPA03009568A (es) | 2004-02-12 |
| WO2002085377A8 (en) | 2002-11-28 |
| US20070286841A1 (en) | 2007-12-13 |
| BRPI0209134B1 (pt) | 2019-08-27 |
| BR0209134A (pt) | 2004-06-15 |
| ES2304437T3 (es) | 2008-10-16 |
| ES2637020T3 (es) | 2017-10-10 |
| US20020187121A1 (en) | 2002-12-12 |
| KR20040018358A (ko) | 2004-03-03 |
| AU2002257145B2 (en) | 2005-06-02 |
| CA2444046C (en) | 2011-06-07 |
| EP1392331B1 (en) | 2008-04-02 |
| NZ528831A (en) | 2005-07-29 |
| CN1511039A (zh) | 2004-07-07 |
| PT1923064T (pt) | 2017-08-23 |
| ATE390927T1 (de) | 2008-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1923064T3 (da) | Anvendelse af aminpolymer til sænkning af serumglucose | |
| AU2002257145A1 (en) | Method for lowering serum glucose | |
| ZA200308063B (en) | Method of lowering serum glucose. | |
| EP1416942B1 (en) | Amine polymers for treating gout and binding uric acid | |
| AU735260C (en) | Polyallylamine polymers for treating hypercholesterolemia | |
| US6281252B1 (en) | Method for reducing oxalate | |
| US20020187120A1 (en) | Method for treating gout and reducing serum uric acid | |
| US6566407B2 (en) | Method for reducing oxalate | |
| AU2005302242A1 (en) | Once a day formulation for phosphate binders | |
| US20020182168A1 (en) | Method for reducing copper levels and treating copper toxicosis | |
| US20020168333A1 (en) | Method for improving vascular access in patients with vascular shunts | |
| EP1923064B1 (en) | Use of amine polymer for lowering serum glucose |